This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In a new report from the NIH Pragmatic Trials Collaboratory, a team of bioethicists explores the ethical obligation to share aggregate results from pragmatic clinical trials with research participants. They conclude with recommendations for how to meet this obligation. The article was published online ahead of print in Clinical Trials. There is growing appreciation of the importance of sharing aggregate results of clinical trials with research participants.
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Novocure, a global leader in oncology innovation, has long been at the forefront of advancing tumor treating fields (TTFields) therapy. This technology, already approved by the US Food and Drug Administration (FDA) for glioblastoma and mesothelioma , and most recently for metastatic non-small cell lung cancer (NSCLC), harnesses electric fields to disrupt cancer cell division.
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
Turkiye’s pharmaceutical industry has grappled with significant economic challenges such as the frequent upward revision of the pharmaceutical Euro exchange rate.
Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and is now available through the NHS.
MRI scans of the human brain. (corelens/Canva) Decreases in brain volume are used as an indicator of Alzheimer’s disease, yet the latest class of Alzheimer’s treatments cause the brain to shrink even further. A new study now suggests this might paradoxically be a good thing.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a significant breakthrough in treatment
Tune in to the podcast interview with Dr Sharmeen Roy to learn more about precision dosing and how DoseMe is providing effective and safe treatment for all through personalised dosing solutions.
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Get to know Jackie Marchington, an expert in IPG Health Medical Communications, through this exclusive interview. Learn about her insights, experiences, and perspectives on the industry.
In December 2022, Congress passed the Food and Drug Omnibus Reform Act (FDORA) requiring drug and device manufacturers to develop and submit diversity action plans (DAPs) for Phase III and other pivotal trials outlining how they plan to recruit, enroll, and retain a population that reflects the patient population with the disease or condition in the US that is expected to use the medical product if approved, licensed, authorized, cleared, or classified.
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Centre Study Location Research Centre: Multidisciplinary Alfred Psychiatry Research Centre Location: Level 4, 607 St Kilda Road, Melbourne 3004 Lead Researcher: Professor Jayashri Kulkarni AM HREC: This study has been reviewed and approved by a Human Research Ethics Committee About the Study Are there new options that could make living with anorexia easier?
Diagnostic et surveillance des maladies infectieuses Event type: symposium Audience: health professionals scientists specialist in clinical biology university staff Description: Organised by Sciensano, under the auspices of the Belgian Public Health Association ( BAPH ) Sciensano organises each year a scientific seminar about Diagnostic and surveillance of infectious diseases.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content